1995
DOI: 10.1074/jbc.270.6.2620
|View full text |Cite
|
Sign up to set email alerts
|

Phosphorothioate Oligodeoxynucleotides Bind to Basic Fibroblast Growth Factor, Inhibit Its Binding to Cell Surface Receptors, and Remove It from Low Affinity Binding Sites on Extracellular Matrix

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
176
0

Year Published

1997
1997
2008
2008

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 310 publications
(179 citation statements)
references
References 32 publications
2
176
0
Order By: Relevance
“…Substitution of the phosphodiester backbone of native DNA with phosphorothioate moieties markedly augments resistance to nuclease digestion. 35,36 Phosphorothioates, however, have also been found to bind with high affinity to a large number of proteins 37,38 presumably the result of alterations in the presentation of negative charges. Without appropriate controls, sequence-independent effects caused by phosphorothioate chemistry can be mistakenly attributed to a true antisense effect.…”
Section: Discussionmentioning
confidence: 99%
“…Substitution of the phosphodiester backbone of native DNA with phosphorothioate moieties markedly augments resistance to nuclease digestion. 35,36 Phosphorothioates, however, have also been found to bind with high affinity to a large number of proteins 37,38 presumably the result of alterations in the presentation of negative charges. Without appropriate controls, sequence-independent effects caused by phosphorothioate chemistry can be mistakenly attributed to a true antisense effect.…”
Section: Discussionmentioning
confidence: 99%
“…3' exonucleases are thought to be more active than 5' exonucleases, so an amine group was added at the 3'-end, this modi®cation having been previously shown to increase the stability of classical phosphodiester antisense ODNs to levels similar to those for phosphothioate ODNs and the stability of the ODNstarget complex. In addition, these 3'-modi®ed ODNs are not toxic and do not compete with FGF1 and 2 for their binding sites (heparin-like activity), in contrast to phosphorothioate ODNs (Fennwald and Rando, 1995;Gukova et al, 1995). We used lipofectin (GIBCO/BRL, Cergy Pontoise, France) as a cationic lipid to deliver the ODNs, because this method results in high levels of uptake and stability of phosphodiester ODNs in the intracellular compartment without a ecting their ®nal nuclear location (Clarenc et al, 1993;Lezoulac'h et al, 1995) after endocytosis and release from the endocytic compartment.…”
Section: Oligonucleotides and Oligonucleotide Treatment Of Cellsmentioning
confidence: 99%
“…However, preclinical and clinical studies showed that PS ASOs may have nonspecific effects, either due to nonsequence specific binding or activation of nonspecific mechanisms. In fact, it has been demonstrated that PS ASOs are able to bind to heparin-binding proteins, such as bFGF, PDGF, VEGF and their receptors (Fennewald and Rando, 1995;Guvakova et al, 1995). Under certain circumstances, PS ASOs are able to activate SP1 transcription factor and their degradation products can affect cell proliferation and differentiation (Perez et al, 1994).…”
Section: Antisense Therapy: Rationale and Limitationsmentioning
confidence: 99%